Sitagliptin, in another study, decreased the development of intestinal ulcers and aided ulcer healing via the ileal GLP-1/2 pathway, implying that sitagliptin might have a clinical role in the management of ileal disorders such as gastroenteritis and Crohn’s disease (Fujiwara et al. 2015). This evidence concerns the gene GLP1R and Crohn disease.